In fact, the previously reported beneficial effects of fenofibrate in the course of bacterial infections are related to the activation of PPAR-α coupled with a reduction in inflammatory processes associated with pathogen virulence, rather than as a bactericidal or bacteriostatic drug [22]. This evidence concerns the gene PPARA and bacterial infectious disease.